Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Lierman, E

Class:Id	Person:1606511
_displayName	Lierman, E
_timestamp	2011-09-22 17:33:16
created	[InstanceEdit:1606512] Rothfels, K, 2011-09-22
firstname	Els
initial	E
surname	Lierman
(author)	[LiteratureReference:1606521] The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11) [LiteratureReference:9673573] Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant [LiteratureReference:9674223] FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive Leukemia
[Change default viewing format]

No pathways have been reviewed or authored by Lierman, E (1606511)